BCL2 and acute lymphoblastic leukemia: In contrast to the known immunosuppressive effect of CD73-adenosine signaling in solid tumors [59], there are no data on the CD73 expression on T cells in ALL; however, CD34+CD73+ blasts overexpress multidrug resistance markers such as BCL2, PGP, and MRP1 [60].